A Single-center, Double-blind, Randomised, Placebo-controlled Crossover Study to Evaluate the Effect of Solithromycin on Airway Inflammation in Male and Female Patients With Chronic Obstructive Pulmonary Disease

Trial Profile

A Single-center, Double-blind, Randomised, Placebo-controlled Crossover Study to Evaluate the Effect of Solithromycin on Airway Inflammation in Male and Female Patients With Chronic Obstructive Pulmonary Disease

Suspended
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Solithromycin (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Cempra Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Aug 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Jul 2018.
    • 10 Aug 2016 Status changed from discontinued to suspended with reference to an E-mail from the principal investigator of the study, stating that the trial is on a temporary hold and possibly could start in the year 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top